Illumina (NASDAQ:ILMN) Sets New 12-Month High – Here’s Why

Shares of Illumina, Inc. (NASDAQ:ILMN) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $278.99 and last traded at $273.1990, with a volume of 227282 shares changing hands. The stock had previously closed at $271.90.

Analyst Ratings Changes

ILMN has been the subject of several research analyst reports. Royal Bank Of Canada lifted their price objective on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and raised their target price for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. TD Cowen boosted their price target on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Stifel Nicolaus increased their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Piper Sandler increased their price target on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $204.12.

Illumina Price Performance

The business has a 50-day moving average price of $213.17 and a two-hundred day moving average price of $171.66. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $40.60 billion, a price-to-earnings ratio of 50.33, a price-to-earnings-growth ratio of 3.83 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the business posted $1.19 EPS. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Illumina during the 2nd quarter valued at $3,374,423,000. Capital World Investors boosted its stake in Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the period. WCM Investment Management LLC grew its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA purchased a new position in Illumina during the 2nd quarter valued at about $617,981,000. Finally, Geode Capital Management LLC increased its position in shares of Illumina by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.